Rhabdomyosarcoma Clinical Trials in Philadelphia, Pennsylvania

3 studies are recruiting for rhabdomyosarcoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

    The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

    Stage
    Phase 1
    Ages
    2 to 18
    Site
    The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania
    Locations
    6 in total
    Run by
    ITM Solucin GmbH

    See if you can join NCT06441331 on ClinicalTrials.gov

  2. A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

    This phase III trial compares higher dose chemotherapy, with vincristine, dactinomycin and cyclophosphamide, over a shorter amount of time to lower dose chemotherapy plus maintenance, with vincristine, dactinomycin, cyclophosphamide, irinotecan and vinorelbine, over a longer amount of time, along w…

    Stage
    Phase 3
    Ages
    Up to 50
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Locations
    87 in total
    Run by
    Children's Oncology Group

    See if you can join NCT07466316 on ClinicalTrials.gov

  3. VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

    This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.

    Stage
    Phase 1
    Ages
    0 to 30
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Locations
    7 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT04796012 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.